Pierson Richard N, Dorling Anthony, Ayares David, Rees Michael A, Seebach Jörg D, Fishman Jay A, Hering Bernhard J, Cooper David K C
Division of Cardiac Surgery, Department of Surgery, University of Maryland, Baltimore VAMC, Baltimore, MD 21201, USA.
Xenotransplantation. 2009 Sep-Oct;16(5):263-80. doi: 10.1111/j.1399-3089.2009.00534.x.
Xenotransplantation is one promising approach to bridge the gap between available human cells, tissues, and organs and the needs of patients with diabetes or end-stage organ failure. Based on recent progress using genetically modified source pigs, improving results with conventional and experimental immunosuppression, and expanded understanding of residual physiologic hurdles, xenotransplantation appears likely to be evaluated in clinical trials in the near future for some select applications. This review offers a comprehensive overview of known mechanisms of xenograft injury, a contemporary assessment of preclinical progress and residual barriers, and our opinions regarding where breakthroughs are likely to occur.
异种移植是一种很有前景的方法，可弥合现有人类细胞、组织和器官与糖尿病患者或终末期器官衰竭患者需求之间的差距。基于使用基因改造供体猪的最新进展、常规和实验性免疫抑制效果的改善以及对残留生理障碍的更深入理解，异种移植似乎很可能在不久的将来针对某些特定应用进行临床试验评估。本综述全面概述了异种移植损伤的已知机制，对临床前进展和残留障碍进行了当代评估，并阐述了我们对可能取得突破之处的看法。
